Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10698743 | 0.74 | MEN1 (0.46) | CA12CA1CA2CA9 | |
| SCHEMBL17849587 | 0.72 | CA12 (0.46) | CA12CA1CA2CA9 | |
| SCHEMBL11948980 | 0.67 | — | — | |
| SCHEMBL17849589 | 0.67 | — | — | |
| SCHEMBL15375190 | 0.66 | — | — | |
| SCHEMBL13859953 | 0.66 | CDC25B (0.39) | CA12CA1CA2CA9 | |
| SCHEMBL30912244 | 0.66 | MEN1 (0.48) | — | |
| SCHEMBL28627359 | 0.65 | CA12 (0.33) | CA12CA1CA2CA9 | |
| SCHEMBL2119387 | 0.65 | CA12 (0.35) | CA12CA1CA2CA9 | |
| SCHEMBL518485 | 0.64 | CA12 (0.34) | CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365541-A1 | INHIBITOR OF ENHANCER OF ZESTE HOMOLOGUE 2, AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230248833-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-08-10 | — | — | US | disclosed |
| US-20170121338-A1 | AMINO PRYAN RING DERIVATIVE AND COMPOSITION AND USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD (CN) | 2017-05-04 | — | — | US | disclosed |
| US-9371336-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2016-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121338-A1 | AMINO PRYAN RING DERIVATIVE AND COMPOSITION AND USE THEREOF | DPP4, DPP8, DPP3 | CA12 2205/4885CA1 1384/4885CA2 1494/4885 |
| US-20230365541-A1 | INHIBITOR OF ENHANCER OF ZESTE HOMOLOGUE 2, AND USE THEREOF | EZH2, BMI1, EZH1 | CA12 2325/4885CA1 1767/4885CA2 2320/4885 |
| US-20230248833-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | BTK, WEE1, WEE2 | CA12 3784/4885CA1 3395/4885CA2 3036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.